Literature DB >> 22019184

Antimicrobials in urogenital infections.

Florian M E Wagenlehner1, Björn Wullt, Gianpaolo Perletti.   

Abstract

Urinary tract infections (UTIs) and male genital infections are amongst the most prevalent infections. A prudent antibiotic policy therefore has a large impact on society. The clinical classification in uncomplicated cystitis, uncomplicated pyelonephritis, complicated UTI and genital infections is useful, also for the right choice of antibiotic treatment. In this regard pharmacokinetic and pharmacodynamic aspects have to be considered. Nowadays in uncomplicated cystitis antibiotics exclusively reserved for this indication are preferred, such as fosfomycin trometamol, nitrofurantoin and pivmecillinam, in order to reduce antibiotic pressure in this extremely frequent entity. In complicated UTI a broad bacterial spectrum has to be considered. Different antibiotic substances should be used for treatment, such as penicillins, with β-lactamase inhibitors, cephalosporins or carbapenems, fluoroquinolones, aminoglycosides or cotrimoxazole, if tested susceptible. For genital infections the pharmacokinetic properties of the antibiotics should especially be considered, such as in prostatitis, where mainly fluoroquinolones and macrolides show sufficient pharmacokinetic parameters for treatment of bacterial infections. Furthermore in genital infections fastidious organisms, such as Chlamydia or Mycoplasma spp. have to be considered with respect to their antimicrobial susceptibility.
Copyright © 2011 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22019184     DOI: 10.1016/j.ijantimicag.2011.09.004

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  9 in total

1.  Application of DNA chip scanning technology for automatic detection of Chlamydia trachomatis and Chlamydia pneumoniae inclusions.

Authors:  Anita Bogdanov; Valeria Endrész; Szabolcs Urbán; Ildikó Lantos; Judit Deák; Katalin Burián; Kamil Önder; Ferhan Ayaydin; Péter Balázs; Dezso P Virok
Journal:  Antimicrob Agents Chemother       Date:  2013-11-04       Impact factor: 5.191

2.  A new anti-microbial combination prolongs the latency period, reduces acute histologic chorioamnionitis as well as funisitis, and improves neonatal outcomes in preterm PROM.

Authors:  JoonHo Lee; Roberto Romero; Sun Min Kim; Piya Chaemsaithong; Chan-Wook Park; Joong Shin Park; Jong Kwan Jun; Bo Hyun Yoon
Journal:  J Matern Fetal Neonatal Med       Date:  2015-09-16

3.  Susceptibility of multiresistant gram-negative bacteria to fosfomycin and performance of different susceptibility testing methods.

Authors:  L V Perdigão-Neto; M S Oliveira; C F Rizek; C M D M Carrilho; S F Costa; A S Levin
Journal:  Antimicrob Agents Chemother       Date:  2013-12-09       Impact factor: 5.191

4.  Prulifloxacin vs fosfomycin for prophylaxis in female patients with recurrent UTIs: a non-inferiority trial.

Authors:  Elisabetta Costantini; Alessandro Zucchi; Eleonora Salvini; Annarita Cicalese; Vincenzo Li Marzi; Maria Teresa Filocamo; Vittorio Bini; Massimo Lazzeri
Journal:  Int Urogynecol J       Date:  2014-02-20       Impact factor: 2.894

5.  Pentacyclic triterpenes combined with ciprofloxacin help to eradicate the biofilm formed in vitro by Escherichia coli.

Authors:  Dorota Wojnicz; Dorota Tichaczek-Goska; Marta Kicia
Journal:  Indian J Med Res       Date:  2015-03       Impact factor: 2.375

Review 6.  Role of Old Antibiotics in the Era of Antibiotic Resistance. Highlighted Nitrofurantoin for the Treatment of Lower Urinary Tract Infections.

Authors:  Maria Jose Munoz-Davila
Journal:  Antibiotics (Basel)       Date:  2014-02-10

7.  Pharmacokinetics and Pharmacodynamics of Fosfomycin and Its Activity against Extended-Spectrum-β-Lactamase-, Plasmid-Mediated AmpC-, and Carbapenemase-Producing Escherichia coli in a Murine Urinary Tract Infection Model.

Authors:  Ilya Nikolaevich Zykov; Ørjan Samuelsen; Lotte Jakobsen; Lars Småbrekke; Dan I Andersson; Arnfinn Sundsfjord; Niels Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

8.  Carbapenem-resistant Klebsiella pneumonia infection outbreak in a tertiary urology clinic: analysis of influencing factors with a controlled trial

Authors:  Fuat Kizilay; Bayram Aliyev; Adnan Şimşir; Serdar Kalemci; Timur Köse; Meltem Taşbakan; Hüsnü Pullukçu
Journal:  Turk J Med Sci       Date:  2020-02-13       Impact factor: 0.973

9.  The Enhancement of the Photodynamic Therapy and Ciprofloxacin Activity against Uropathogenic Escherichia coli Strains by Polypodium vulgare Rhizome Aqueous Extract.

Authors:  Dorota Tichaczek-Goska; Michał Gleńsk; Dorota Wojnicz
Journal:  Pathogens       Date:  2021-11-25
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.